Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Triple Negative Breast Neoplasms 2 Sarcoma 2 Prostatic Neoplasms 2 Breast Neoplasms 2 Uveal Melanoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Platinum-Refractory Fallopian Tube Carcinoma 1 Pancreatic Neoplasms 1 Neoplasms 1 Melanoma 1 Lymphoma 1 Liposarcoma 1 Fallopian Tube Neoplasms 1 Carcinoma, Squamous Cell 1 Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Rituximab 20 Cyclophosphamide 18 Etoposide 11 Vincristine 10 Doxorubicin 10 fludarabine phosphate 9 Prednisone 9 Filgrastim 9 Radiotherapy 8 Peripheral Blood Stem Cell Transplantation 8 Cytarabine 8 Methotrexate 7 Melphalan 7 Dexamethasone 6 fludarabine 4 Cyclosporine 4 Antilymphocyte Serum 4 duvelisib 3 belinostat 3 Thiotepa 3 Tacrolimus 3 Nivolumab 3 Mycophenolic Acid 3 Lenalidomide 3 Ifosfamide 3 Gemcitabine 3 Carmustine 3 Busulfan 3 Alemtuzumab 3 sargramostim 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Lymphoma × olaparib × Clear all

NCT03575078 2019-09-25

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

University of Texas Southwestern Medical Center

Phase 1 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡